SuperworthIntegra Lifesciences profit margin IART
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 0.8%
- Operating margin, 12 months
- 4.4%
- Net margin on a year earlier
- +30.9 pts
- Peer median
- 6.5%
Over the twelve months to Sep 30, 2026, Integra Lifesciences kept 0.8% of its revenue as net profit, with an operating margin of 4.4% and a gross margin of 52.4%.
Five years earlier its net margin was 14.2%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −31.6% | −30.2% | 50.9% |
| FY2024 | −0.4% | 1.8% | 54.8% |
| FY2023 | 4.4% | 7.2% | 57.4% |
| FY2022 | 11.6% | 15.3% | 62.3% |
| FY2021 | 11.0% | 12.8% | 61.2% |
| FY2020 | 9.8% | 11.0% | 62.0% |
| FY2019 | 3.3% | 6.2% | 62.8% |
| FY2018 | 4.1% | 7.5% | 61.2% |
| FY2017 | 5.4% | 3.8% | 63.3% |
| FY2016 | 7.5% | 11.6% | 64.8% |
| FY2015 | −0.4% | 9.0% | 63.0% |
| FY2014 | 4.3% | 8.5% | 69.7% |
| FY2013 | −2.5% | −1.2% | 60.9% |
| FY2012 | 5.0% | 8.9% | 62.2% |
| FY2011 | 3.6% | 7.0% | 61.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q3 FY26 | 0.8% | +30.9 pts | 4.4% | |
| Q2 FY26 | −0.4% | +30.4 pts | 4.0% | |
| Q1 FY26 | −30.1% | −28.4 pts | −28.4% | |
| Q4 FY25 | −31.6% | −31.2 pts | −30.2% | |
| Q3 FY25 | −30.1% | −29.7 pts | −29.3% | |
| Q2 FY25 | −30.9% | −32.4 pts | −30.9% | |
| Q1 FY25 | −1.8% | −4.4 pts | 0.6% | |
| Q4 FY24 | −0.4% | −4.8 pts | 1.8% | |
| Q3 FY24 | −0.4% | −7.0 pts | 1.8% | |
| Q2 FY24 | 1.5% | −7.0 pts | 4.1% | |
| Q1 FY24 | 2.6% | −8.4 pts | 5.2% | |
| Q4 FY23 | 4.4% | −7.2 pts | 7.2% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Integra Lifesciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| IARTIntegra Lifesciences | −0.4% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| MOVMovado | 6.0% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| EYENational Vision | 2.5% |
| MDXGMimedx | 1.8% |
| TCMDTactile Systems Technology | 7.1% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| Peer median | 6.5% |
Where Integra Lifesciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Integra Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.